Profits up, R&D investments down at biotechs

04/23/2013 | Bloomberg · PharmaTimes (U.K.)

Biotech companies are slowing the growth in research and development spending even as profits rise worldwide. R&D spending grew by 5% last year, compared with 9% growth in 2011, and revenue grew by 8%. Companies increasingly look beyond regulatory approval and consider payer reimbursement potential when deciding whether to pursue drug candidates or acquisition targets, experts say.

View Full Article in:

Bloomberg · PharmaTimes (U.K.)

Published in Brief: